Logos Capital

Founded 2019
Founders Dr. Arsani William Edward Zhong Graham Walmsley


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 60
Average round size
The average size of a deal this fund participated in
Portfolio companies 56
Rounds per year 30.00
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 24
Key employees Soon
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Quanta Therapeutics

Health Care
Medical Device
$60M26 Oct 2021 San Francisco, California, United States

Cedilla Therapeutics

Health Care
$25M25 Oct 2021 Cambridge, Massachusetts, United States

Neumora Therapeutics

Health Care
$400M07 Oct 2021 Watertown, Massachusetts, United States

Expansion Therapeutics

Health Care
$80M29 Sep 2021 San Diego, California, United States

858 Therapeutics

Health Care
$60M21 Sep 2021 San Diego, California, United States

Ventyx Biosciences

$51M20 Sep 2021 Encinitas, California, United States

Alpine Immune Sciences

Health Care
$91M15 Sep 2021 Seattle, Washington, United States


Health Care
Health Diagnostics
Medical Device
$24M09 Sep 2021 Seattle, Washington, United States


Health Care
$116M08 Sep 2021 San Francisco, California, United States
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Logos Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: